Durable benefit and slowdown in tumor growth dynamics with erdafitinib in a FGFR3-TACC3 fusion-positive IDH-wild type glioblastoma
Neuro-Oncology Advances · 01.01.2024 · 6 (1)
DOI: 10.1093/noajnl/vdae139 ↗Kurz gefasst
Fachartikel in der Zeitschrift Neuro-Oncology Advances, online erschienen am 06.08.2024. Verfasst von Santiago Cabezas-Camarero und 7 weiteren Autor:innen. Beteiligte Einrichtung: Medical Oncology Department, IOB Institute of Oncology-Madrid, Madrid, Spain. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Grupo Español de Investigación en Neuro-Oncología, Johnson & Johnson Innovative Medicine, Erdafitinib.
Abstract (Originalsprache)
FGFR3-TACC3 fusion-positive IDH-wild-type (IDH-WT) glioblastoma (GB) is a rare GB subtype occurring in approximately 3% of cases. It is clinical behavior and molecular profile is different from those of fusion-negative IDH-WT GBs. Evidence on the role of FGFR inhibitors in FGFR-altered gliomas is limited. We present the case of a patient with a FGFR3-TACC3 fusion-positive IDH-WT GB that at its second recurrence was treated with the FGFR inhibitor erdafitinib through a compassionate use program. Although no objective response was achieved, an overt deceleration in tumor growth was evidenced and the patient remained on treatment for 5.5 months.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Medical Oncology Department, IOB Institute of Oncology-Madrid, Madrid, Spain.
- Medical Oncology Department, Instituto de Investigación Sanitaria San Carlos (IdISSC), Hospital Clínico Universitario San Carlos, Madrid, Spain.
- Neurosurgery Department, Hospital Clínico Universitario San Carlos, Madrid, Spain.
- Radiology Department, Hospital Clínico Universitario San Carlos, Madrid, Spain.
- Pathology Department, Hospital Clínico Universitario San Carlos, Madrid, Spain.
ORCID-Profile: Santiago Cabezas-Camarero
Förderung
- Grupo Español de Investigación en Neuro-Oncología
- Johnson & Johnson Innovative Medicine
- Erdafitinib
- Astex Pharmaceuticals
Zitieren
APA
Cabezas-Camarero, S., Pérez-Alfayate, R., Polidura, C., Gómez-Ruiz, M. N., Gil-Martínez, L., Casado-Fariñas, I., Bartolomé, J., & Pérez-Segura, P. (2024). Durable benefit and slowdown in tumor growth dynamics with erdafitinib in a FGFR3-TACC3 fusion-positive IDH-wild type glioblastoma. Neuro-Oncology Advances, 6(1). https://doi.org/10.1093/noajnl/vdae139
Vancouver
Cabezas-Camarero S, Pérez-Alfayate R, Polidura C, Gómez-Ruiz MN, Gil-Martínez L, Casado-Fariñas I, et al. Durable benefit and slowdown in tumor growth dynamics with erdafitinib in a FGFR3-TACC3 fusion-positive IDH-wild type glioblastoma. Neuro-Oncology Advances. 2024;6(1). doi:10.1093/noajnl/vdae139
BibTeX
@article{CabezasCamarero2024,
author = {Cabezas-Camarero, Santiago and Pérez-Alfayate, Rebeca and Polidura, Carmen and Gómez-Ruiz, María Natividad and Gil-Martínez, Lidia and Casado-Fariñas, Isabel and Bartolomé, Jorge and Pérez-Segura, Pedro},
title = {Durable benefit and slowdown in tumor growth dynamics with erdafitinib in a FGFR3-TACC3 fusion-positive IDH-wild type glioblastoma},
journal = {Neuro-Oncology Advances},
year = {2024},
volume = {6},
number = {1},
doi = {10.1093/noajnl/vdae139}
}
EUVIMED